Aera Therapeutics

About Aera Therapeutics

Aera Therapeutics is dedicated to unlocking the potential of genetic medicines to transform human health. Their mission focuses on addressing the critical challenge of delivery in the field of genetic medicines, aiming to revolutionize treatment across various therapeutic applications.

Products & Services

Targeted Lipid Nanoparticles (tLNPs):A proprietary delivery platform for next-generation genetic medicines.

Antibody Oligonucleotide Conjugates (AOCs):A delivery technology designed to enable genetic medicines across different therapeutic modalities.

Protein Nanoparticles (PNPs):A platform to overcome limitations of current delivery technologies for genetic medicines.

Specialties

Genetic Medicines Delivery Platforms Therapeutic Modalities

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A and B T: - FT: Series A and B	A: 193000000 MR: - FA: $193 million FAN: 193000000	D: 2023-02-16 FD: 2023-02-16	3 investors

Series A and B Latest

2023-02-16

$193.0M

3 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Akin Akinc

Chief Executive Officer

H

Husain Attarwala

Vice President of Bioanalytics, DMPK, Clinical Pharmacology, and Analytics

S

Scott Barros

Senior Vice President of Early Development

F

Felipe Bendezu

Director of Molecular Technologies

P

Paul Conrad

Chief Business and Financial Officer

R

Robert Dorkin

Senior Director of Delivery Technologies

View 15 more team members with Pro

Unlock Full Team Directory

Recent News